GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » International Biotechnology Trust PLC (CHIX:IBTl) » Definitions » Capex-to-Revenue

International Biotechnology Trust (CHIX:IBTL) Capex-to-Revenue : 0.00 (As of Aug. 2024)


View and export this data going back to 2015. Start your Free Trial

What is International Biotechnology Trust Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

International Biotechnology Trust's Capital Expenditure for the six months ended in Aug. 2024 was £0.00 Mil. Its Revenue for the six months ended in Aug. 2024 was £11.02 Mil.

Hence, International Biotechnology Trust's Capex-to-Revenue for the six months ended in Aug. 2024 was 0.00.


International Biotechnology Trust Capex-to-Revenue Historical Data

The historical data trend for International Biotechnology Trust's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

International Biotechnology Trust Capex-to-Revenue Chart

International Biotechnology Trust Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

International Biotechnology Trust Semi-Annual Data
Feb15 Aug15 Feb16 Aug16 Feb17 Aug17 Feb18 Aug18 Feb19 Aug19 Feb20 Aug20 Feb21 Aug21 Feb22 Aug22 Feb23 Aug23 Feb24 Aug24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of International Biotechnology Trust's Capex-to-Revenue

For the Biotechnology subindustry, International Biotechnology Trust's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


International Biotechnology Trust's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, International Biotechnology Trust's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where International Biotechnology Trust's Capex-to-Revenue falls into.


;
;

International Biotechnology Trust Capex-to-Revenue Calculation

International Biotechnology Trust's Capex-to-Revenue for the fiscal year that ended in Aug. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 40.14
=0.00

International Biotechnology Trust's Capex-to-Revenue for the quarter that ended in Aug. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 11.015
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


International Biotechnology Trust  (CHIX:IBTl) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


International Biotechnology Trust Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of International Biotechnology Trust's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


International Biotechnology Trust Business Description

Traded in Other Exchanges
Address
1 London Wall Place, London, GBR, EC2Y 5AU
International Biotechnology Trust PLC is an investment trust company. It aims at achieving long-term capital growth by investing in biotechnology and other life sciences companies. It seeks to achieve its objective by investing in a diversified portfolio of companies which has good growth prospects. It focuses on investments in biotechnology companies which are engaged in on drug discovery and development, medical devices companies and healthcare services provider. The invests in various financial instruments such as equities, index-linked securities, debt securities, cash deposits, money market instruments ,and foreign currency exchange transactions. Its revenue comprises of dividend, interest and other income from investment made.

International Biotechnology Trust Headlines